Literature DB >> 34196861

Chronological Trends of Breast Ductal Carcinoma In Situ: Clinical, Radiologic, and Pathologic Perspectives.

Si Eun Lee1, Ha Yan Kim2, Jung Hyun Yoon3, Eun-Kyung Kim1, Jee Ye Kim4, Min Jung Kim3, Ga Ram Kim3, Youngjean Vivian Park3, Hee Jung Moon5.   

Abstract

BACKGROUND: Because no prior studies have evaluated the chronological trends of ductal carcinoma in situ (DCIS) despite the increasing number of surgeries performed for DCIS, this study analyzed how the clinical, radiologic, and pathologic characteristics of DCIS changed during a 10-year period.
METHODS: Of 7123 patients who underwent primary breast cancer surgery at a single institution from 2006 to 2015, 792 patients with pure DCIS were included in this study. The chronological trends of age, symptoms, method for detecting either mammography or ultrasonography, tumor size, nuclear grade, comedonecrosis, and molecular markers were calculated using Poisson regression for all patients and asymptomatic patients.
RESULTS: During 10 years, DCIS surgery rates significantly increased (p < 0.001). Despite the high percentage of DCIS detected on mammography, the detection rate for DCIS by mammography significantly decreased (97.3% in 2006 to 67.6% in 2015; p = 0.025), whereas the detection rate by ultrasound significantly increased (2.7% to 31.0%; p < 0.001). Conservation surgery rates (odds ratio [OR], 1.058), low-to-intermediate nuclear grade rates (OR, 1.069), and the absence of comedonecrosis (OR, 1.104) significantly increased over time (all p < 0.05). Estrogen receptor (ER) negativity (OR, 0.935) and human epidermal growth factor receptor 2 (HER2) positivity rates (OR, 0.953) significantly decreased (all p < 0.05). The same trends were observed for the 613 asymptomatic patients.
CONCLUSION: The rate of DCIS detected on ultrasound only significantly increased during 10 years. Low-to-intermediate nuclear grade rates significantly increased, whereas ER negativity and HER2 positivity rates significantly decreased during the same period. These findings suggest that DCIS detected on screening ultrasound is less aggressive than DCIS detected on mammography.

Entities:  

Year:  2021        PMID: 34196861     DOI: 10.1245/s10434-021-10378-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  42 in total

1.  Rethinking the Standard for Ductal Carcinoma In Situ Treatment.

Authors:  Laura Esserman; Christina Yau
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

2.  Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast.

Authors:  Laura A Lee; Melvin J Silverstein; Cathie T Chung; Heather Macdonald; Premal Sanghavi; Melinda Epstein; Dennis R Holmes; Howard Silberman; Wei Ye; Michael D Lagios
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

Review 3.  Treatment of low-risk ductal carcinoma in situ: is nothing better than something?

Authors:  John R Benson; Ismail Jatoi; Masakazu Toi
Journal:  Lancet Oncol       Date:  2016-10       Impact factor: 41.316

4.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Steven A Narod; Javaid Iqbal; Vasily Giannakeas; Victoria Sopik; Ping Sun
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

5.  Addressing overtreatment of screen detected DCIS; the LORIS trial.

Authors:  Adele Francis; Jeremy Thomas; Lesley Fallowfield; Matthew Wallis; John M S Bartlett; Cassandra Brookes; Tracy Roberts; Sarah Pirrie; Claire Gaunt; Jennie Young; Lucinda Billingham; David Dodwell; Andrew Hanby; Sarah E Pinder; Andrew Evans; Malcolm Reed; Valerie Jenkins; Lucy Matthews; Maggie Wilcox; Patricia Fairbrother; Sarah Bowden; Daniel Rea
Journal:  Eur J Cancer       Date:  2015-08-18       Impact factor: 9.162

Review 6.  Ductal Carcinoma In Situ: The Whole Truth.

Authors:  Ujas Parikh; Chloe M Chhor; Cecilia L Mercado
Journal:  AJR Am J Roentgenol       Date:  2017-10-18       Impact factor: 3.959

7.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Authors:  Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2011-03-11       Impact factor: 13.506

8.  Characterizing the impact of 25 years of DCIS treatment.

Authors:  Elissa M Ozanne; Yiwey Shieh; James Barnes; Colleen Bouzan; E Shelley Hwang; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

9.  Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast.

Authors:  Lina Romero; Laura Klein; Wei Ye; Dennis Holmes; Rashida Soni; Howard Silberman; Michael D Lagios; Melvin J Silverstein
Journal:  Am J Surg       Date:  2004-10       Impact factor: 2.565

Review 10.  Ductal carcinoma in situ: to treat or not to treat, that is the question.

Authors:  Maartje van Seijen; Esther H Lips; Alastair M Thompson; Serena Nik-Zainal; Andrew Futreal; E Shelley Hwang; Ellen Verschuur; Joanna Lane; Jos Jonkers; Daniel W Rea; Jelle Wesseling
Journal:  Br J Cancer       Date:  2019-07-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.